HNF’s CMT Genie: Because genetic testing for CMT has never been more critical

by | Feb 7, 2024 | 0 comments

Collaborative efforts between researchers, healthcare providers, and patients, facilitated by the Hereditary Neuropathy Foundation, has created a synergy that has accelerated the pace of discovery. Genetic testing not only benefits individual patients but also contributes to the collective knowledge that can improve the understanding and management of CMT on a broader scale.

Clinical Trials are on the Horizon 

The landscape of CMT research is evolving quickly – particularly for the most common type, CMT1A. Advances in genetic testing technologies and our understanding of genetic contributions to diseases are influencing the design of clinical trials to target specific patient subgroups for more personalized and effective treatments. Clinical trials are essential for evaluating the safety and efficacy of new treatments, drugs, or interventions. However, the success of a clinical trial depends on recruiting participants who are not only willing but also suitable candidates based on their CMT subtype.

Avoid Neurotoxic Drugs

Without genetic confirmation, patients may unknowingly be prescribed neurotoxic drugs (some as common as antibiotics, vitamins, and antidepressants), which can lead to loss of muscle strength, sensation, mobility, and additional symptoms including pain, numbness, and unpredictable complications. It may take years before the permanent and accelerated decline is associated with a neurotoxic drug.

Early Interventions Can Help

Due to the progressive nature of CMT, early interventions such as bracing, physical and occupational therapy, proper nutrition, and mental health and community support can have a positive impact and, in some cases, slow the progression of comorbidities and loss of function.

Family Planning

Genetic testing plays a crucial role in family planning and genetic counseling. Genetic testing allows for informed family planning decisions, enabling individuals to make choices that align with their values and preferences. Moreover, genetic counseling provides emotional support and guidance for individuals and families navigating the complexities of rare diseases. Genetic counselors help interpret test results, discuss potential implications, and address psychosocial concerns.

ARE YOU READY FOR CMT CLINICAL TRIALS?

  • Make an appointment with CMT Genie for genetic counseling and testing
  • Join HNF’s patient registry, GRIN and consent to be contacted if you are a match for a clinical trial
  • Upload your genetic report to GRIN
  • Complete all GRIN surveys

Learn more on this topic

Related Blog Posts

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news